Prevalence and Risk Factor of Post-intensive Care Syndrome in Neuro-ICU
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 11, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a condition called Post-intensive Care Syndrome (PICS), which can cause problems for patients after they leave the intensive care unit (ICU). PICS can lead to difficulties with physical function, thinking, and mental health, significantly affecting a person's quality of life. The study aims to understand how common PICS is among patients with neurological diseases, both when they leave the ICU and three months later. It will also try to figure out what factors might increase the risk of developing these symptoms.
To participate in this trial, individuals must have spent more than 24 hours in the ICU due to a neurological condition, and they must have received certain treatments, such as breathing support or other invasive therapies. The trial is open to all adults aged 65 to 74, as long as they or their designated support person do not oppose their participation. It's important to note that individuals who are minors, pregnant, or have severe pre-existing conditions may not be eligible. Participants can expect to be monitored for their symptoms and receive support throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient with \> 24h stay in intensive care unit
- • 2.Patients with a neurological disease affecting the central or peripheral nervous system, which is the reason for their hospitalization in intensive care.
- • 3. Patients who have received organ replacement or invasive therapy in the ICU (invasive or non-invasive ventilation, extra-renal purification, plasmapheresis, ventricular bypass, catecholamines).
- • 4. Non-opposition of the patient or of the trusted support person, or of a family member or close friend if the patient is unable to express non-opposition.
- Exclusion Criteria:
- • 1. Minors, protected adults and pregnant women
- • 2. Advanced neurodegenerative disease pre-existing prior to ICU admission
- • 3. Severe psychotic disorders pre-existing before admission to intensive care
- • 4. Patients whose neurological and psychiatric history is unknown prior to resuscitation
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Paris, , France
Patients applied
Trial Officials
Clémence Marois, MD, MSc
Principal Investigator
Assisitance Publique des Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported